CJC-1295 without DAC 5 mg – Short-acting GHRH analogue

What is CJC-1295 without DAC (CJC-1295 no DAC)?

CJC-1295 without DAC (also known as CJC-1295 no DAC, Modified GRF 1-29, Mod GRF 1-29) is a synthetic, short-acting GHRH analog — the growth-hormone-releasing hormone. It is a modified GRF (1-29) fragment with four amino-acid substitutions (D-Ala², Gln⁸, Ala¹⁵, Leu²⁷) that confer resistance to breakdown by the peptidase DPP-4 and other plasma proteases, while preserving a short, physiological profile of action.

The term „without DAC" is key. DAC (Drug Affinity Complex) is an albumin-binding group which, in the „with DAC" version, extends the half-life to several days and maintains a constant, elevated GH background. The without-DAC version does not have this group — its half-life is about 30 minutes, so it produces short, pulsatile GH peaks that more closely mimic the natural rhythm of growth hormone secretion by the pituitary.

CJC-1295 without DAC acts on the GHRH receptor in the pituitary. This distinguishes it from the GHRP class / ghrelin mimetics (like GHRP-2 or Hexarelin), which act on a separate receptor, GHS-R1a. Because these are two different pathways, in studies they are combined for a synergistic effect — hence the popularity of the CJC-1295 with GHRP / Ipamorelin combination.

CJC-1295 without DAC is studied in the context of the GH/IGF-1 axis, regeneration, body composition and lipolysis. It is a research peptide — it holds no registration as a medicinal product in the EU. See also the other recovery and anabolic peptides in our category.

In the version offered by Peptology, CJC-1295 without DAC is supplied as a lyophilized peptide with purity above 99% (HPLC/MS), confirmed by independent laboratory analysis (CoA for every batch), in a 5 mg vial format. The product is intended exclusively for scientific research and in vitro applications and is not a medicinal product.

Available format: 5 mg

CJC-1295 without DAC is available in a lyophilized 5 mg format, which covers typical scales of research work — from single in vitro series to longer GH-axis protocols, including combination schedules with GHRP peptides.

The 5 mg format has purity > 99% and a laboratory certificate for the batch. The choice of amount depends on the scale of the protocol, not on the concentration of the active substance.

How CJC-1295 without DAC works — stimulation of the GHRH axis

In the research literature, CJC-1295 without DAC is described as a molecule that stimulates the GHRH receptor in the pituitary and triggers a short, pulsatile GH peak. The three features below together determine its profile — physiological and short, in contrast to the extended-action with-DAC version.

Without DAC vs with DAC — what the difference is

This is the most common question about CJC-1295. The with-DAC version has an attached albumin-binding group, which extends the half-life to several days and maintains a constant, elevated GH/IGF-1 background („GH bleed"). The without-DAC version (this product) acts briefly (~30 min) and produces single, physiological GH pulses. In studies on pulsatility and mimicking the natural rhythm, the without-DAC form is more often chosen; where the goal is a constant background — the with-DAC form.

Because the GHRH (CJC-1295) and GHS-R1a (GHRP / ghrelin) pathways are independent, in research protocols a GHRH analog is combined with a secretagogue — e.g. GHRP-2, Hexarelin or Ipamorelin. These data come from pharmacological studies and do not constitute a claim about the effect of the research-grade product.

Pharmacokinetics and pharmacodynamics of CJC-1295 without DAC

CJC-1295 without DAC is a short-acting GHRH analog which, in the published pharmacological data, is described as a molecule with a short half-life and a fast, pulsatile profile of action on the GH axis.

• Biological half-life: about 30 minutes (no albumin-binding DAC group)
• GH peak: usually within 15–30 minutes of subcutaneous administration, returning to baseline shortly afterward
• Profile of action: short, pulsatile — it mimics the natural rhythm of GH secretion
• Target: GHRH receptor in the pituitary (cAMP pathway)
• Enzymatic stability: 4 amino-acid substitutions confer resistance to DPP-4 and plasma proteases
• Research schedule: because of the short profile, subcutaneous administration is usually used in protocols, often in combination with GHRP

CJC-1295 without DAC vs Sermorelin vs GHRP-2

The table below compares CJC-1295 without DAC with two other GH-axis tools in the catalog. Sermorelin is another GHRH analog (acting on the same receptor), and GHRP-2 is a ghrelin mimetic acting on a separate receptor, GHS-R1a. The comparison shows why GHRH analogs and secretagogues are often combined in studies. The data are scientific and comparative in nature.

The pharmacokinetic values are approximate and come from the pharmacological literature on GHRH analogs and GH secretagogues. The table is scientific and comparative in nature and does not constitute a direct head-to-head comparison or a claim about the effect of the research-grade product.

Clinical and preclinical data on CJC-1295

CJC-1295 is a research molecule — it has not gone through a phase 3 registration program like prescription medicines. Most of the controlled clinical data concern the DAC-modified, extended-action form, whereas the without-DAC form is used in studies because of its short, pulsatile profile. Below are the most important observations from the literature.

Early clinical trials (DAC form)

In published early clinical trials of CJC-1295 with DAC in healthy adults, a dose-dependent, sustained increase in GH and IGF-1 concentrations was documented after subcutaneous administration, with good tolerability. They served as proof of concept that an extended-action GHRH analog can raise the GH/IGF-1 axis.

Pulsatile profile of the without-DAC form

In research models, the without-DAC form (Mod GRF 1-29) is described as producing short GH peaks within 15–30 minutes, mimicking the endogenous secretion rhythm. This makes it a tool for research on GH-axis pulsatility, rather than on a constant, elevated background.

GHRH + GHRP synergy

In pharmacological studies, combining a GHRH analog (like CJC-1295) with a GHRP secretagogue (like Ipamorelin, GHRP-2 or Hexarelin) is associated with a 3–5-fold higher GH release than either component alone, because they act on separate receptors (GHRH-R and GHS-R1a).

Note: The information is presented for scientific and informational purposes and is based on the pharmacological literature and early clinical trials. It does not constitute medical advice, a recommendation for use or a claim about the effect of the research-grade product offered by Peptology.

CJC-1295 without DAC profile at a glance

• Short-acting GHRH analog (Mod GRF 1-29) — pulsatile GH-axis stimulation mimicking the natural rhythm
• Half-life ~30 min thanks to the absence of the DAC group — GH peak within 15–30 minutes
• 3–5× synergy with GHRP peptides (Ipamorelin, GHRP-2, Hexarelin) — two separate receptors
• Resistance to DPP-4 thanks to four amino-acid substitutions
• Studied in the context of GH/IGF-1, regeneration, body composition and lipolysis
• Good tolerability in observations — predominantly mild, local reactions

All information provided concerns pharmacological literature and early research on CJC-1295 and should not be interpreted as a promise of effect, an instruction for use or a claim about the effect of the research-grade product offered by Peptology.

Research dosing protocols

Because of its short half-life, CJC-1295 without DAC is used in studies differently from extended-action forms — subcutaneous administration, usually in combination with GHRP:

• Observations at a dose of ~10 µg/kg per day (up to 16 weeks) described a GH/IGF-1 increase consistent with the natural rhythm
• Protocols often use a so-called saturating GHRH dose subcutaneously, on an empty stomach
• The short profile favors administration in the peri-workout period or before sleep (pulsatile models)
• Combination schedules: GHRH analog + GHRP (Ipamorelin / GHRP-2 / Hexarelin) for a synergistic effect

Unlike long-acting molecules (like the with-DAC form), CJC-1295 without DAC has a short window of action — which is why in pulsatile models it is administered more frequently and in combination with a secretagogue. These schedules come from the research literature and do not constitute a recommendation for self-administration. You will find the ready-made complex as CJC-1295 + Ipamorelin.

Side effects and safety

In research observations, CJC-1295 without DAC is described as well tolerated, with predominantly local and mild side effects. Most of them are dose-dependent and reversible.

Most observed side effects are mild, local and reversible and dose-dependent. This information is scientific in nature and does not constitute an instruction for use.

Storage and reconstitution

CJC-1295 without DAC is supplied as a lyophilized (freeze-dried) powder in a vial. In lyophilized form the peptide is stable at room temperature, protected from light and moisture — refrigeration before reconstitution is not mandatory. After reconstitution, stability depends on the solvent used, with Peptide Matrix Water™ significantly extending the peptide's lifespan.

• Before reconstitution: room temperature, in the original packaging, protected from light and moisture. A refrigerator is not mandatory.
• After reconstitution with Peptide Matrix Water™: stability in the refrigerator +2 °C to +8 °C for up to 60 days under appropriate laboratory conditions — the stabilizing formula extends the peptide's lifespan relative to standard solvents.
• After reconstitution with bacteriostatic or sterile water: stability in the refrigerator +2 °C to +8 °C for up to 28 days under appropriate conditions. Do not refreeze the reconstituted solution.
• Reconstitution: in a laboratory setting, Peptide Matrix Water™, bacteriostatic water or sterile water for injection is usually used, depending on the protocol.
• Volume: maximum 3 mL of solvent (capacity of a standard vial). For a precise calculation of volume and units, use the peptide calculator.
• Homogenization: add the solvent slowly down the vial wall, without vigorous shaking — peptide bonds are sensitive to mechanical stress. Swirl gently, do not shake.

Laboratory tip: With your order, you can add Peptide Matrix Water™ to the cart — a stabilizing solution designed for working with reconstituted research peptides. More in the article Bacteriostatic water vs acetic acid vs matrix water.

Frequently asked questions about CJC-1295 without DAC

What exactly is CJC-1295 without DAC?

It is a short-acting GHRH analog (Modified GRF 1-29) that stimulates the GHRH receptor in the pituitary and triggers pulsatile release of growth hormone. It mimics the natural rhythm of GH secretion. The results come from the pharmacological and research literature.

CJC-1295 without DAC or with DAC — what is the difference?

The without-DAC version has a short half-life (~30 min) and produces pulsatile GH peaks mimicking the natural rhythm. The with-DAC version has an attached albumin-binding group, so it acts for several days and maintains a constant, elevated GH/IGF-1 background. The choice depends on the goal of the research protocol.

Can it be combined with GHRP peptides?

Yes — this is a classic research schedule. The GHRH analog (CJC-1295) acts on the GHRH receptor, and GHRP (like GHRP-2, Hexarelin or Ipamorelin) on the GHS-R1a receptor. Combining the two pathways gives a 3–5-fold higher GH release in studies. The ready-made complex is CJC-1295 + Ipamorelin.

What is the half-life of CJC-1295 without DAC?

About 30 minutes — it is precisely the absence of the DAC group (albumin-binding) that is responsible for the short profile. The GH peak usually appears within 15–30 minutes of subcutaneous administration.

How does CJC-1295 differ from Sermorelin?

Both are GHRH analogs acting on the same receptor, but CJC-1295 (Mod GRF 1-29) has four amino-acid substitutions increasing resistance to DPP-4, which translates into a slightly more stable profile than Sermorelin. Both are studied as a GHRH base, often in combination with GHRP.

How is CJC-1295 without DAC stored and reconstituted?

The lyophilized vial is stored at room temperature, protected from light and moisture — without the need for cooling before reconstitution. After reconstitution, stability depends on the solvent: with Peptide Matrix Water™ — up to 60 days in the refrigerator +2 °C to +8 °C; with bacteriostatic or sterile water — up to 28 days. Avoid refreezing.

Where to buy CJC-1295 without DAC for research?

Peptology offers CJC-1295 without DAC 5 mg as a research peptide with confirmed purity above 99% (HPLC/MS) and independent laboratory analysis for every batch. Fast shipping, discreet packaging and certificates of purity with the product. For scientific background, also see the article Peptides — what they are, how they work, main categories and safety profile.

Related peptides in the Peptology catalog

Researchers working with CJC-1295 without DAC often also consider other GH-axis tools — GHRH analogs, GHRP secretagogues and ready-made complexes. Each of the products below has a certificate of purity above 99%:

See the full catalog: Recovery and anabolic peptides · Solutions for peptides · Blog on peptide research

Molecule identity

Laboratory reconstitution

Laboratory protocol — reconstitution, research protocols, storage

Standardized protocol applicable to all research peptides in the Peptology catalogue. To calculate the solution concentration (mg/mL) for each vial, use the peptide reconstitution calculator.

60-second protocol

Quick reference

What you need

Five rules for reconstitution

Calculating concentration

Storage

Four mistakes to avoid

Shipping information

🚚 Shipping information

• Products in our warehouse – orders placed by 15:00 on working days are dispatched the same day, later orders on the next working day.

• Delivery with GLS to your address in 3–5 working days.

• Shipping costs €5 and is free from €50.

Frequently Asked Questions (FAQ)

CJC without DAC or with DAC – what is the difference?

CJC without DAC has a shorter half-life and stimulates natural GH pulses, while the DAC version maintains a steady level with prolonged action.

In what form is CJC-1295 without DAC supplied and how should it be stored?

It is supplied as a lyophilized (freeze-dried) powder in a sealed vial. Store the unopened vial dry and protected from light, ideally at 2–8 °C. After laboratory reconstitution, keep the solution at 2–8 °C and use it within the period stated in the “Laboratory reconstitution” tab (up to 60 days with Peptide Matrix Water).

Is a prescription required?

No. The product is for laboratory and research use only.

Where can I buy CJC‑1295 without DAC in Europe and what does it cost?

You can buy CJC‑1295 without DAC in Europe online from Peptology, from 25,00 €. Delivery with GLS in 3–5 working days. Shipping is free from 50,00 €. Payment by card. Purity 99%+, with an HPLC report for every batch.

Laboratory Analysis

CJC‑1295 without DAC - 5mg - Batch - 0226 - Purity